Evidence map›Paper›PMID 29795140›Full record

ReviewProstate cancer and prostatic diseases2018

The microbiome in prostate inflammation and prostate cancer.

Corey M Porter, Eva Shrestha, Lauren B Peiffer, Karen S Sfanos

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Prostate cancer and prostatic diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03709485 (Analysis of Gut Microbiome in Prostate Cancer Patients), which is not on this map. Cited by 135 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 8 pooled it
15.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03709485 naunknown statusnot on this map

Analysis of Gut Microbiome in Prostate Cancer Patients

TypeinterventionalSponsorZiv HospitalRan2018 to 2019Enrolled150ConditionsProstate CancerArmsrectal swab for microbial culture.
3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 8 syntheses or guidelines pooled it, 197 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. The urinary tract commensalApplied and environmental microbiology · 2026
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. The Urinary Tract commensalbioRxiv : the preprint server for biology · 2026
    Article
  18. Article
  19. Review
  20. Review

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Corey M PorterDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Eva ShresthaDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Lauren B PeifferDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Karen S SfanosDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ksfanos@jhmi.edu.ORCID http://orcid.org/0000-0002-7015-3059
Johns Hopkins University · US

Funding

Training Program in Cellular and Molecular MedicineT32GM008752 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAO, RAJINI · 2000 to 2019
$11.7M
6 · The paper itself

Abstract

backgroundThe human microbiome may influence prostate cancer initiation and/or progression through both direct and indirect interactions. To date, the majority of studies have focused on direct interactions including the influence of prostate infections on prostate cancer risk and, more recently, on the composition of the urinary microbiome in relation to prostate cancer. Less well understood are indirect interactions of the microbiome with prostate cancer, such as the influence of the gastrointestinal or oral microbiota on pro- or anti-carcinogenic xenobiotic metabolism, and treatment response.

methodsWe review the literature to date on direct and indirect interactions of the microbiome with prostate inflammation and prostate cancer.

resultsEmerging studies indicate that the microbiome can influence prostate inflammation in relation to benign prostate conditions such as prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia, as well as in prostate cancer. We provide evidence that the human microbiome present at multiple anatomic sites (urinary tract, gastrointestinal tract, oral cavity, etc.) may play an important role in prostate health and disease.

conclusionsIn health, the microbiome encourages homeostasis and helps educate the immune system. In dysbiosis, a systemic inflammatory state may be induced, predisposing remote anatomical sites to disease, including cancer. The microbiome's ability to affect systemic hormone levels may also be important, particularly in a disease such as prostate cancer that is dually affected by estrogen and androgen levels. Due to the complexity of the potential interconnectedness between prostate cancer and the microbiome, it is vital to further explore and understand the relationships that are involved.

Indexed as

Disease ProgressionHumansMaleMicrobiotaProstateProstatic HyperplasiaProstatic NeoplasmsProstatitisXenobioticsXenobiotics

Identifiers

PMID29795140
OpenAlexW2803354726

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.